Abstract We have previously shown in the post ischemic gut that enteral arginine enhanced injury and inflammation via c-Jun/AP-1 and abrogated peroxisome proliferatoractivated receptor (PPAR) c activity. In the current study, we investigated the mechanism by which arginine inhibited PPARc in vitro in rat small bowel epithelial IEC-6 cells. Arginine repressed PPARc transcriptional activity in a time and dose-dependent fashion. Furthermore, downregulation of PPARc by arginine involved phosphorylation of c-Jun that occurred before to changes in PPARc transcriptional activity. Silencing of c-Jun increased PPARc beyond that of nonsilenced cells and was not mitigated by arginine. Using a series of blocking studies, we found no relationship between arginine and the ligand-dependent binding site of PPARc. In conclusion, arginine decreased PPARc transcriptional activity in small bowel intestinal epithelial cells. These changes are due, in part, to phosphorylation of c-Jun and may explain the deleterious effects of enteral arginine in the post ischemic gut.
Introduction
L-arginine (arginine) is a conditionally essential amino acid but becomes essential in disease states [1] [2] [3] . It plays an important role in cell growth, proliferation, migration, and particularly immune function [4, 5] . In the intestine, arginine accelerates intestinal mucosal regeneration, enhances bacterial clearance, and reduces bowel necrosis [6] . A recent metaanalysis demonstrated a significant decrease in post operative infections in patients receiving supplemental arginine before major surgery [7] . Ochoa et al. have demonstrated that myeloid suppressor cells secrete arginase, leading to an arginine deficient state, and subsequent repressed T cell function [8, 9] . Arginine supplementation restored T cell function and lessened infectious complications. However, other investigators have suggested that critically ill patients, particularly those with sepsis, may not benefit or may even be harmed from arginine supplementation. Systemic inflammation may be intensified by arginine via inducible nitric oxide synthase (iNOS) [5, 10, 11] . We have shown in a rodent model of gut ischemia/reperfusion that enteral arginine increases gut injury and inflammation and enhances iNOS production [12] .
Peroxisome proliferator-activated receptor (PPAR)c is a member of the nuclear receptor superfamily. PPARs are ligand-dependent transcription factors that bind to specific peroxisome proliferator response elements (PPRE) at the enhancer sites of regulated genes [13] . PPARc plays a critical role in the immune response through suppression of inflammatory cytokines and to direct the differentiation of immune cells toward anti-inflammatory phenotypes [14] .
The transcriptional activity of PPARc is regulated through several distinct mechanisms, including liganddependent transactivation, ligand-independent repression, and ligand-dependent transrepression [15] . PPARc is a heterodimer transcription factor composed of PPARc and retinoid X receptor (RXR). The heterodimer is associated with the nuclear receptor corepressor complex in the absence of PPARc ligand. Upon activation by a ligand, the corepressor complex is replaced by coactivators leading to transcriptional initiation of target genes. The coactivators of PPARc include p300/CREB binding protein (CBP), p160, PPARc coactivator-1, thyroid hormone receptorassociated protein 220 or PPARc-binding protein, androgen receptor-associated protein, and PPARc-interacting protein. The corepressor for PPARc is a protein complex containing histone deacetylase 3 and silencing mediator for retinoic and thyroid hormone receptors or nuclear corepressor, and possibly, receptor-interacting protein [16] .
PPARc is also a phosphoprotein. Its transcriptional activity is affected by kinases, notably the mitogen-activated protein kinases (MAPK), including both extracellular signal-regulated protein kinase (ERK) and the c-Jun NH 2 -terminal kinase (JNK), but also protein kinase A and C, AMP kinase and glycogen synthase kinase-3 [17, 18] .
We have shown in a rodent model of gut ischemia/ reperfusion that arginine enhanced activator protein 1 (AP-1) via c-Jun but inhibited PPARc DNA-binding activity [19] . AP-1 is a stress-activated DNA-binding protein composed of subunits that belong to the c-Fos and c-Jun families whose activities are regulated by MAPK. JNK phosphorylates a number of transcription factors, including the c-Jun component of the AP-1 transcription factor complex. c-Jun is involved in the regulation of diverse biological processes, including proliferation, inflammation, differentiation, apoptosis, and cell migration [20, 21] . JNK can phosphorylate c-Jun on Ser63, Ser73, Thr91, and Thr93 within its transcriptional activation domain [22] . We have also shown in vitro that inhibition of JNK repressed arginine-mediated inflammation as well as c-Jun phosphorylation [23] . In the present study, we hypothesized that phosphorylation of c-Jun by arginine would inhibit PPARc transcriptional activity in a ligand-independent fashion.
Materials and methods

Chemicals and reagents
The specific PPARc agonist, rosiglitazone, and antagonist, GW9662, were obtained from Cayman Chemical (Ann Arbor, MI, USA). Antibodies against c-Jun, phospho-c-Jun (Ser63) II (p-c-Jun), and b-actin were from Cell Signaling (Danvers, MA, USA). Antibody against PPARc was the product of Santa Cruz (Santa Cruz, CA, USA). ECL antirabbit IgG, horseradish peroxidase linked whole antibody (donkey) and ECL plus Western blotting detection system were purchased from GE Healthcare Bio-sciences Corp (Piscataway, NJ, USA). Dual-luciferase reporter assay system was ordered from Promega Corporation (Madison, WI, USA). Lipofectamine 2000 and Dulbecco's modified Eagle's medium (DMEM) and DMEM without arginine were from Invitrogen (Carlsbad, CA, USA). Arginine and D-arginine were the products of Sigma (Milwaukee, WI, USA).
Cell line
The rat small intestinal cell line, IEC-6, was purchased from the American Type Culture Collection and cultured using Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine and 100 U/ml penicillin, and 100 lg/ml streptomycin in a humidified atmosphere containing 5% CO 2 at 37°C.
Western blot IEC-6 cells were lysed with radioimmunoprecipitation assay buffer containing protease inhibitors (Sigma, Milwaukee, WI, USA). Proteins in the cell lysates were separated by electrophoresis on sodium dodecyl sulfate-polyacrylamide gel and transferred onto a Hybond-P membrane (Amersham Biosciences). The membrane was blocked with 5% fat-free milk in tris buffered saline with 0.1% Tween 20 for 1 h at room temperature, and incubated overnight at 4°C with antibody against phospho-c-Jun (Ser63), c-Jun, PPARc or b-actin. The blot was then incubated for 1 h at room temperature with ECL anti-rabbit IgG, horseradish peroxidase linked whole antibody (from donkey), developed with ECL plus Western blotting detection system, and exposed onto film. The immunoblot band was quantified by densitometry and normalized to b-actin. The relative expression value in the control group was designated as 1.
RNA silencing of c-Jun
Pre-designed rat c-Jun siRNA (part number: 4390815) and negative control siRNA #1 (cat # 4611) (scrambled siRNA) were purchased from Ambion (Austin, TX, USA). The c-Jun siRNA duplex oligonucleotide sense sequence was as follows: 5 0 -GGCACAGCUUAAACAGAAAtt-3 0 . Interference transfections were performed with the silencer siRNA Starter Kit according to the manufacture's instructions.
Isolation of total RNA and real-time PCR Total RNA was extracted from cells by the TRIzol isolation method according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA) and reverse transcribed using an iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA) following the manufacturers' instructions. Primers for rat b-actin (Rn00667 869-m1) and PPARc (Rn00440945_m1) were obtained from Applied Biosystems (Austin, TX, USA). Primer for rat c-Jun was: 5 0 -CGGCCCCGAAACTTCTG-3 0 (forward) and 5 0 -GTCGTTTCCATCTTTGCAGTCA-3 0 (reverse) [24] . Real-time PCR assays were performed in 96-well optical plates on an ABI Prism 7000 Sequence Detection System with SYBR Green PCR Master Mix (Applied Biosystems, Austin, TX, USA). Gene expression was normalized against that of b-actin. The value for control cells was set to 1 and the value for the various treatments was presented as a fraction of this number.
Luciferase reporter gene assay
The luciferase reporter construct pGAL3 Basic or PPRE X3-TK-Luc (Addgene, Cambridge, MA, USA) [25] was transiently co-transfected into c-Jun siRNA transfected or untransfected IEC-6 cells at approximately 95% confluency with the Renilla control vector using Lipofectamine 2000. The PPRE-X3-TK-Luc reporter vector contains three copies of the PPRE upstream of the thymidine kinase promoter-luciferase fusion gene. After 24 h of transfection, cells were cultured in DMEM without arginine and FBS overnight. Cells were then treated with arginine (0-20 mM) based on previous studies with glutamine [26] and cultured for indicated time points. For PPARc agonist and antagonist treatment, 10 lM of GW9662 (maximum effect on inhibition PPARc in IEC-6 cells, data not shown) and rosiglitazone [27] , or vehicle was added to cells 1 h before arginine treatment. Subsequently, total cell lysates were prepared using 1X passive lysis buffer. Luciferase and Renilla activities were determined using a dual-luciferase assay system in a Turner Designs TD-20/20 luminometer (Turner Designs) according to manufacturer's instructions. Background values from pGL3 basic transfected cells were subtracted from all luciferase and Renilla readings. The luciferase values were then normalized to Renilla values.
Data analysis
Statistical analysis was performed by one way analysis of variance and individual group means compared using Tukey's multiple group comparison test. P values \ 0.05 were considered significant. Data are expressed as mean ± SEM and all experiments were performed in triplicate.
Results
Arginine increased phospho-c-Jun in small bowel intestinal epithelial cells
To validate our in vivo finding that arginine increased intestinal c-Jun activity [19] , we examined c-Jun and phospho-c-Jun expression after arginine administration in small bowel intestinal epithelial cells. A time and dosedependent increase in phospho-c-Jun expression by arginine was demonstrated (Fig. 1a, b) . Expression increased by 1 h, returned to baseline by 8 h, and was maximal after 10 mM of arginine. To confirm that the increase in phospho-c-Jun was specific, expression in response to D-arginine, an inactive form of arginine [28, 29] , was also measured. As shown in Fig. 1c , D-arginine did not increase phosphorylation of c-Jun (Fig. 1c) .
PPARc transcriptional activity is decreased by arginine
To gain preliminary insight into the role of arginine as a potential PPARc antagonist, the expression of PPARc in response to arginine stimulation was analyzed. There was no change in PPARc mRNA over time by arginine confirmed by quantitative PCR (data not shown). Immunoblotting similarly revealed no change in protein expression (data not shown). However, time course and dose response experiments showed that PPARc transcriptional activity decreased at 2 h, remained repressed through 8 h, and was maximal after 10 mM of arginine (Fig. 2a, b) . Importantly, the decrease in PPARc transcriptional activity occurred at later timepoints (Fig. 2b) than the increase in phospho-c-Jun (Fig. 1b) .
Repression of PPARc activity by arginine is not via the ligand-dependent binding site
To determine if arginine was regulating the transcriptional activity of PPARc via ligand-dependent transrepression [15] , the PPARc binding site was either activated by ligand or blocked by antagonist before arginine administration. Rosiglitazone is a thiazolidinedione that is a high affinity synthetic ligand of PPARc, whereas GW9662 (2-chloro-5nitrobenzanilide) is an irreversible antagonist that covalently modifies a cysteine residue in the ligand binding domain of PPARc [30] [31] [32] . Western blot analysis demonstrated that phospho-c-Jun expression was not altered by either Rosiglitazone (10 lM) or GW9662 (10 lM) (data not shown), suggesting that c-Jun did not affect the ligand-dependent binding domain of PPARc in small bowel epithelial cells and PPARc is the downstream of c-Jun.
Cells were next treated with either arginine, GW9662, or both, and PPARc transcriptional activity measured. Activity was significantly decreased by either arginine or GW9662, but the combined treatment further significantly decreased activity below that of either alone (Fig. 3) , consistent with a mechanism that does not involve arginine binding to the ligand-dependent binding site.
Arginine has no effect on PPARc activity in c-Jun silenced cells
The amino terminal A/B domain of PPARc contains a ligandindependent activation function (AF-1) which is phosphorylated at a consensus MAPK site, including Jun NH 2 -terminal kinase (JNK) [33] . JNK then phosphorylates a number of transcription factors, including the c-Jun component of the AP-1 transcription factor complex. Our current findings suggested arginine decreased PPARc activity by phosphorylation of c-jun. To confirm these findings, a small RNA interference approach was utilized. c-Jun expression was silenced by 81.5% at the mRNA level (Fig. 4a) and 82.4% at (Fig. 4b) . PPARc transcriptional activity in c-Jun silenced cells was significantly enhanced (Fig. 4c) , showing that PPARc is the target of c-Jun activation. Importantly, PPARc transcriptional activity was not repressed by arginine in c-Jun silenced cells (Fig. 5) . In addition, inhibition of the ligand-dependent binding site by GW9662 decreased transcriptional activity to that of nonsilenced cells and activity was not restored by arginine (Fig. 5) . These studies suggested that inhibition of PPARc activity by arginine is at the ligand-independent activation site.
Discussion
In the current study, we demonstrated that arginine repressed PPARc transcriptional activity in small bowel epithelial cells in a time and dose-dependent fashion. Furthermore, downregulation of PPARc by arginine involved phophorylation of c-Jun that occurred before changes in PPARc transcriptional activity. Silencing of c-Jun increased PPARc activity beyond that of nonsilenced cells and was not mitigated by arginine. Using a series of blocking studies, we found no relationship between arginine and the ligand-dependent binding site of PPARc.
There has been little investigation into the regulation of PPARc by arginine. Liu et al. reported that arginine supplementation in a sepsis model increased PPARc mRNA in the intestines of pigs [34] . The reason for the differences between Liu's findings and the current study are unclear, particularly when Zigarelli et al. and others have demonstrated inhibition of PPARc in sepsis [35, 36] . We have also shown inhibition of intestinal PPARc by arginine in the post ischemic gut [12, 19] .
Nuclear receptors in general, and PPARc in particular, can be activated by ligand-dependent and independent mechanisms. The synergistic repressive effect of GW9662 and arginine on PPARc activity suggested that arginine may regulate the activity of PPARc, at least in part, via a ligand-independent manner. Activation by ligand-independent mechanisms typically involves kinase-dependent processes. PPARc is a phosphoprotein and MAPKs, like JNK, decrease its transcriptional activity [33, 37] . The phosphorylation site on PPARc by JNK has been mapped to a site with both ligand-dependent and independent functions [33] . As suggested by Camp et al. [38] , phosphorylation of PPARc by the JNK pathway could reduce the effectiveness of activating ligands. We have shown that glutamine activates PPARc via endogenous ligands [39] but when administered with arginine to intestinal epithelial cells, the profound protective effects of glutamine were significantly abrogated (unpublished observations). The mechanism by which c-Jun regulates the activity of PPARc is not completely understood. CBP and its homologue p300 are transcriptional co-activators of various sequence-specific transcription factors including PPARc. The two homologous cofactors p300 and CREB binding protein have been shown to co-activate the ligand-dependent and -independent transcriptional activities of PPARc [40] and can interact with c-Jun [41, 42] . Thus, it is possible that c-Jun may compete with p300 and CREB binding protein to suppress the activity of PPARc. Another possibility is that c-Jun via AP-1 exerts its suppression of PPARc. Fu et al. reported that AP-1 markedly inhibited PPARc promoter activity in transient-transfection studies in vascular smooth muscle cells [43] .
In conclusion, arginine decreased PPARc transcriptional activity in small bowel intestinal epithelial cells. These changes are due, in part, to phosphorylation of c-Jun and may explain the deleterious effects of enteral arginine in the post ischemic gut [12, 19] . 
